{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:42:20Z","timestamp":1779147740382,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anaerobe"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.anaerobe.2018.10.011","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T11:39:19Z","timestamp":1541158759000},"page":"35-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["A systematic review of the use of rifaximin for Clostridium difficile infections"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8561-2513","authenticated-orcid":false,"given":"Qin Xiang","family":"Ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayren","family":"Loke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine Xinhui","family":"Foo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wee-Song","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex Yu Sen","family":"Soh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anaerobe.2018.10.011_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1469-0691.2006.01580.x","article-title":"Emergence of Clostridium difficile-associated disease in North America and Europe","volume":"12","author":"Kuijper","year":"2006","journal-title":"Clinical microbiology and infection"},{"issue":"3","key":"10.1016\/j.anaerobe.2018.10.011_bib2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cgh.2006.12.027","article-title":"Incidence of Clostridium difficile infection in inflammatory bowel disease","volume":"5","author":"Rodemann","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.anaerobe.2018.10.011_bib3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9759","key":"10.1016\/j.anaerobe.2018.10.011_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(10)61266-4","article-title":"Clostridium difficile infection in Europe: a hospital-based survey","volume":"377","author":"Bauer","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.anaerobe.2018.10.011_bib5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect. Contr. Hosp. Epidemiol."},{"issue":"15","key":"10.1016\/j.anaerobe.2018.10.011_bib6","article-title":"Antibiotic-associated colitis","volume":"30","author":"Bartlett","year":"1984","journal-title":"Disease-a-Month"},{"issue":"11","key":"10.1016\/j.anaerobe.2018.10.011_bib7","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1086\/430311","article-title":"Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole","volume":"40","author":"Musher","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.anaerobe.2018.10.011_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2307\/30145589","article-title":"Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982\u20131991","volume":"15","author":"Olson","year":"1994","journal-title":"Infect. Contr. Hosp. Epidemiol."},{"key":"10.1016\/j.anaerobe.2018.10.011_bib9","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0924-8579(09)70014-7","article-title":"Recurrent Clostridium difficile infection: causality and therapeutic approaches","volume":"33","author":"Johnson","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"5","key":"10.1016\/j.anaerobe.2018.10.011_bib10","first-page":"tax025","article-title":"A\u00a0meta-analysis of the use of rifaximin to prevent travellers' diarrhoea","volume":"24","author":"Ng","year":"2017","journal-title":"J.\u00a0Trav. Med."},{"issue":"2","key":"10.1016\/j.anaerobe.2018.10.011_bib11","first-page":"51","article-title":"Pharmacokinetic study of rifaximin after oral administration in healthy volunteers","volume":"14","author":"Descombe","year":"1994","journal-title":"Int. J. Clin. Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.anaerobe.2018.10.011_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000007297","article-title":"In\u00a0vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species","volume":"46","author":"Marchese","year":"2000","journal-title":"Chemotherapy"},{"key":"10.1016\/j.anaerobe.2018.10.011_bib13","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.anaerobe.2018.10.011_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1756283X10372985","article-title":"Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial","volume":"3","author":"Basu","year":"2010","journal-title":"Therapeutic advances in gastroenterology"},{"issue":"1","key":"10.1016\/j.anaerobe.2018.10.011_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MCG.0b013e31814a4e97","article-title":"Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study","volume":"43","author":"Garey","year":"2009","journal-title":"J.\u00a0Clin. Gastroenterol."},{"issue":"12","key":"10.1016\/j.anaerobe.2018.10.011_bib16","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/jac\/dkr377","article-title":"A\u00a0randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection","volume":"66","author":"Garey","year":"2011","journal-title":"J.\u00a0Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.anaerobe.2018.10.011_bib17","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1097\/MIB.0000000000001249","article-title":"Metronidazole or rifaximin for treatment of clostridium difficile in pediatric patients with inflammatory bowel disease: a randomized clinical trial","volume":"23","author":"Gawronska","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"issue":"6","key":"10.1016\/j.anaerobe.2018.10.011_bib18","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1086\/511870","article-title":"Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin","volume":"44","author":"Johnson","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.anaerobe.2018.10.011_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.anaerobe.2009.08.004","article-title":"Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment","volume":"15","author":"Johnson","year":"2009","journal-title":"Anaerobe"},{"issue":"1","key":"10.1016\/j.anaerobe.2018.10.011_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/apt.12111","article-title":"Rifaximin in the treatment of recurrent Clostridium difficile infection","volume":"37","author":"Mattila","year":"2013","journal-title":"Aliment Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.anaerobe.2018.10.011_bib21","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/cid\/cix918","article-title":"Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin","volume":"66","author":"Reigadas","year":"2017","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.anaerobe.2018.10.011_bib22","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In\u00a0vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.anaerobe.2018.10.011_bib23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.anaerobe.2010.09.002","article-title":"Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains","volume":"16","author":"Huang","year":"2010","journal-title":"Anaerobe"},{"issue":"4","key":"10.1016\/j.anaerobe.2018.10.011_bib24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1086\/596315","article-title":"High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital","volume":"48","author":"Curry","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.anaerobe.2018.10.011_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.anaerobe.2017.10.002","article-title":"Rifaximin-resistant Clostridium difficile strains isolated from symptomatic patients","volume":"48","author":"Reigadas","year":"2017","journal-title":"Anaerobe"},{"issue":"8","key":"10.1016\/j.anaerobe.2018.10.011_bib26","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1128\/AAC.00342-08","article-title":"Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile","volume":"52","author":"O'Connor","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.anaerobe.2018.10.011_bib27","first-page":"843","article-title":"The specific inhibition of DNA-directed RNA synthesis by rifamycin","volume":"145","author":"Hartmann","year":"1967","journal-title":"Biochem. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.anaerobe.2018.10.011_bib28","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","article-title":"In\u00a0vitro activity and fecal concentration of rifaximin after oral administration","volume":"44","author":"Jiang","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.anaerobe.2018.10.011_bib29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.dld.2018.04.020","article-title":"New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases","volume":"50","author":"Bajaj","year":"2018","journal-title":"Dig. Liver Dis."},{"issue":"9","key":"10.1016\/j.anaerobe.2018.10.011_bib30","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1128\/AAC.00161-10","article-title":"Bile acids improve the antimicrobial effect of rifaximin","volume":"54","author":"Darkoh","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.anaerobe.2018.10.011_bib31","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijantimicag.2009.11.013","article-title":"Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei","volume":"35","author":"Jiang","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"7","key":"10.1016\/j.anaerobe.2018.10.011_bib32","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.clinthera.2011.06.007","article-title":"Rifaximin: new therapeutic indication and future directions","volume":"33","author":"Rivkin","year":"2011","journal-title":"Clin. Therapeut."},{"issue":"8","key":"10.1016\/j.anaerobe.2018.10.011_bib33","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.mayocp.2015.04.016","article-title":"Therapeutic effects and mechanisms of action of rifaximin in gastrointestinal diseases","volume":"90","author":"DuPont","year":"2015","journal-title":"InMayo Clinic Proceedings"},{"issue":"6","key":"10.1016\/j.anaerobe.2018.10.011_bib34","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s10620-013-2675-0","article-title":"The effect of rifaximin on gut flora and Staphylococcus resistance","volume":"58","author":"Kim","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.anaerobe.2018.10.011_bib35","first-page":"dkq345","article-title":"Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in\u00a0vitro approach using a continuous culture colonic model system","author":"Maccaferri","year":"2010","journal-title":"J.\u00a0Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.anaerobe.2018.10.011_bib36","first-page":"979","article-title":"Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin","volume":"12","author":"De Leo","year":"1985","journal-title":"Drugs Under Exp. Clin. Res."}],"container-title":["Anaerobe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1075996418301835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1075996418301835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T18:58:59Z","timestamp":1550516339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1075996418301835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":36,"alternative-id":["S1075996418301835"],"URL":"https:\/\/doi.org\/10.1016\/j.anaerobe.2018.10.011","relation":{},"ISSN":["1075-9964"],"issn-type":[{"value":"1075-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of the use of rifaximin for Clostridium difficile infections","name":"articletitle","label":"Article Title"},{"value":"Anaerobe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anaerobe.2018.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}